EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Standard Versus Reduced Hydration to Improve Elimination of High‐Dose Methotrexate in Pediatric Patients: A Controlled Crossover Trial

Cady Noda iD, Lindsey Gwaltney, Roy Sabo, Megan Lo, Matthew Schefft iD

Pediatric Blood & Cancer · 2025-04 · 72 (4)

DOI: 10.1002/pbc.31566 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 27.01.2025. Verfasst von Cady Noda und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Children's Hospital of Richmond at VCU Health, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Methotrexate, Antimetabolites, Antineoplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Fluid Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hydration and urine alkalinization are the mainstays for the prevention of methotrexate‐induced nephrotoxicity. Current oncology protocols recommend pediatric patients who are administered high‐dose methotrexate (HDMTX) to be aggressively hydrated with an alkaline solution, which may lead to overhydration. This pilot study sought to determine whether reduced posthydration results in a shorter time to methotrexate elimination without increasing adverse effects.

Methods

A prospective randomized controlled crossover study design of pediatric patients with acute lymphoblastic leukemia was performed. Patients were randomized to begin with standard or reduced volume intravenous fluids. Over the course of four cycles of HDMTX, patients alternated between the standard rate of 125 mL/m 2 /h and a reduced volume rate of 62.5 mL/m 2 /h. The primary endpoint was the time from the start of HDMTX to a serum methotrexate concentration less than 0.1 µmol/L.

Results

Data from 37 HDMTX courses were analyzed in 10 patients aged 1–17 years. The median time to methotrexate elimination was similar between the standard and reduced hydration regimens at 71.7 h (60.8–115.6 h) versus 72.9 h (59.9–132 h, p value = 0.6539). There was no difference in the change from baseline to maximum creatinine (10% vs. 18.9%, p value = 0.6566), maximum weight gain (0.7 kg vs. 0.4 kg, p value = 0.0967), or rates of severe mucositis between hydration regimens.

Conclusion

Reduced posthydration appeared to be safe and provided similar time to HDMTX elimination. A multicenter study is indicated to confirm the use of reduced hydration to optimize supportive care in pediatric patients administered HDMTX. Trial Registration : NCT03964259.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateAntimetabolites, AntineoplasticPrecursor Cell Lymphoblastic Leukemia-LymphomaFluid TherapyHumansChildChild, PreschoolCross-Over StudiesMaleFemaleAdolescentInfantProspective StudiesPilot ProjectsFollow-Up StudiesPrognosis

Stichwörter der Autor:innen

high‐dose methotrexatehydrationpediatric acute lymphoblastic leukemiasupportive care

Substanzen

MethotrexateAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Pharmacy, Children's Hospital of Richmond at VCU Health, Richmond, Virginia, USA.
  • Massey Comprehensive Cancer Center at VCU Health, Richmond, Virginia, USA.
  • Department of Biostatistics, VCU School of Public Health, Richmond, Virginia, USA.
  • Department of Pediatrics, Children's Hospital of Richmond at VCU Health, Richmond, Virginia, USA.

ORCID-Profile: Cady Noda, Matthew Schefft

Förderung

  • NCI NIH HHS

Zitieren

APA

Noda, C., Gwaltney, L., Sabo, R., Lo, M., & Schefft, M. (2025). Standard Versus Reduced Hydration to Improve Elimination of High‐Dose Methotrexate in Pediatric Patients: A Controlled Crossover Trial. Pediatric Blood & Cancer, 72(4). https://doi.org/10.1002/pbc.31566

Vancouver

Noda C, Gwaltney L, Sabo R, Lo M, Schefft M. Standard Versus Reduced Hydration to Improve Elimination of High‐Dose Methotrexate in Pediatric Patients: A Controlled Crossover Trial. Pediatric Blood & Cancer. 2025;72(4). doi:10.1002/pbc.31566

BibTeX
@article{Noda2025,
  author = {Noda, Cady and Gwaltney, Lindsey and Sabo, Roy and Lo, Megan and Schefft, Matthew},
  title = {Standard Versus Reduced Hydration to Improve Elimination of High‐Dose Methotrexate in Pediatric Patients: A Controlled Crossover Trial},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  volume = {72},
  number = {4},
  doi = {10.1002/pbc.31566}
}
Kostenlos starten →